The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis.

Lipids play an important role in the central nervous system (CNS). They contribute to the structural integrity and physical characteristics of cell and organelle membranes, act as bioactive signalling molecules, and are utilised as fuel sources for mitochondrial metabolism. The intricate homeostatic mechanisms underpinning lipid handling and metabolism across two major CNS cell types; neurons and astrocytes, are integral for cellular health and maintenance. Here, we explore the various roles of lipids in these two cell types. Given that changes in lipid metabolism have been identified in a number of neurodegenerative diseases, we also discuss changes in lipid handling and utilisation in the context of amyotrophic lateral sclerosis (ALS), in order to identify key cellular processes affected by the disease, and inform future areas of research.

Restraint stress increases prolactin-mediated phosphorylation of signal transducer and activator of transcription 5 in the hypothalamus and adrenal cortex in the male mouse.

Prolactin is a pleiotropic peptide hormone produced by the lactotrophs in the anterior pituitary. Its rate of secretion is primarily regulated by a negative-feedback mechanism where prolactin stimulates the activity of the tuberoinfundibular dopaminergic (TIDA) neurones, increasing their release of dopamine, which accesses the pituitary via the median eminence to suppress further prolactin secretion. In addition to its well established role in lactation, circulating prolactin is secreted in response to stress, although the mechanism by which this is achieved or its cellular targets remains unknown. In the present study, we show that 15 minutes of restraint stress causes an approximately seven-fold increase in circulating prolactin concentration in male mice. Monitoring prolactin receptor activation, using immunohistochemistry to determine the level and distribution of tyrosine phosphorylated signal transducer and activator of transcription 5 (pSTAT5), we show that this stress-induced increase in prolactin interacts with both central and peripheral targets. Restraint stress for 15 minutes significantly increased pSTAT5 staining in the arcuate nucleus, median eminence and the zona fasciculata of the adrenal cortex. In each case, this response was prevented by pretreating the animals with bromocriptine to block prolactin secretion from the pituitary. Interestingly, in contrast to many cells in the arcuate nucleus, stress reduced pSTAT5 staining of the TIDA neurones (identified by dual-labelling for tyrosine hydroxylase). This suggests that there is reduced prolactin signalling in these cells and thus potentially a decline in their inhibitory influence on prolactin secretion. These results provide evidence that prolactin secreted in response to acute stress is sufficient to activate prolactin receptors in selected target tissues known to be involved in the physiological adaptation to stress.

Environmental scanning electron microscopy in cell biology.

Environmental scanning electron microscopy (ESEM) (1) is an imaging technique which allows hydrated, insulating samples to be imaged under an electron beam. The resolution afforded by this technique is higher than conventional optical microscopy but lower than conventional scanning electron microscopy (CSEM). The major advantage of the technique is the minimal sample preparation needed, making ESEM quick to use and the images less susceptible to the artifacts that the extensive sample preparation usually required for CSEM may introduce. Careful manipulation of both the humidity in the microscope chamber and the beam energy are nevertheless essential to prevent dehydration and beam damage artifacts. In some circumstances it is possible to image live cells in the ESEM (2).In the following sections we introduce the fundamental principles of ESEM imaging before presenting imaging protocols for plant epidermis, mammalian cells, and bacteria. In the first two cases samples are imaged using the secondary electron (topographic) signal, whereas a transmission technique is employed to image bacteria.

Application of environmental scanning electron microscopy to determine biological surface structure.

The use of environmental scanning electron microscopy in biology is growing as more becomes understood about the advantages and limitations of the technique. These are discussed and we include new evidence about the effect of environmental scanning electron microscopy imaging on the viability of mammalian cells. We show that although specimen preparation for high-vacuum scanning electron microscopy introduces some artefacts, there are also challenges in the use of environmental scanning electron microscopy, particularly at higher resolutions. This suggests the two technologies are best used in combination. We have used human monocyte-derived macrophages as a test sample, imaging their complicated and delicate membrane ruffles and protrusions. We have also explored the possibility of using environmental scanning electron microscopy for dynamic experiments, finding that mammalian cells cannot be imaged and kept alive in the environmental scanning electron microscopy. The dehydration step in which the cell surface is exposed causes irreversible damage, probably via loss of membrane integrity during liquid removal in the specimen chamber. Therefore, mammalian cells should be imaged after fixation where possible to protect against damage as a result of chamber conditions.

Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation.

Currently there is minimal concern that islet allograft failure could result from the development of anti-human leukocyte antigen (HLA) antibodies reactive to the allograft. We report here a case of islet allograft failure where the recipient developed immunoglobulin G anti-HLA class I antibodies reactive to HLA antigens present in two of the three islet cell donors. The patient had no detectable anti-HLA antibodies prior to the transplant but these antibodies were detected approximately 4 months posttransplant. Of concern, these antibodies developed despite induction with anti-IL2R antibodies (Zenapex) prior to intraportal islet cell infusion, low-dose tacrolimus (12-hour troughs 3 to 5 ng/mL) and rapammune (target troughs 12 to 15 ng/mL). The patient was not presensitized with blood products or a previous allograft. Her husband, however, shared antigens present in one of the islet donors and the recipient could have been presensitized to her husband during her two pregnancies. This case clearly demonstrates that islet allografts can lead to development of anti-HLA antibodies, which can cause islet allograft failure, as is the case with solid organ transplants, and hence emphasizes the need to monitor for such antibodies pre- and posttransplant. Additionally it appears that currently recommended immunosuppression may not be sufficient to inhibit a humoral response to both alloantigens and autoantigens.

Sex differences in knee joint laxity change across the female menstrual cycle.

AIM: To elucidate the hormonal influences on sex differences in knee joint behavior, normal-menstruating females were compared to males on serum hormone levels and anterior knee joint laxity (displacement at 46N, 89N and 133N) and stiffness (Linear slope of deltaForce/deltaDisplacement for 46-89N and 89-133N) across the female menstrual cycle. METHODS: Twenty-two females were tested daily across one complete menstrual cycle, and 20 males were tested once per week for 4 weeks. Five days each representing the hormonal milieu for menses, the initial estrogen rise near ovulation, and the early and late luteal phases (total of 20 days) were compared to the average value obtained from males across their 4 test days. RESULTS: Sex differences in knee laxity were menstrual cycle dependent, coinciding with significant elevations in estradiol levels. Females had greater laxity than males on day 5 of menses, days 3-5 near ovulation, days 1-4 of the early luteal phase and days 1, 2, 4 and 5 of the late luteal phases. Within females, knee laxity was greater on day 5 near ovulation compared to day 3 of menses, and days 1-3 of the early luteal phase compared to all days of menses and day 1 near ovulation. On average, differences observed between sexes were greater than those within females across their cycle. There were no differences in anterior knee stiffness between sexes or within females across days of the menstrual cycle.

Retinal oxygen consumption during hyperglycemia in patients with diabetes without retinopathy.

OBJECTIVE: This study aimed to determine whether retinal oxygen consumption in patients with diabetes without retinopathy is affected by acute changes in blood glucose. DESIGN: The study design was a nonrandomized, interventional clinical study. PARTICIPANTS: The study consisted of 12 patients with diabetes without ophthalmoscopically visible diabetic retinopathy whose ages were 20 to 59 years (mean, 33.7 years). INTERVENTION: Retinal vessel oximetry was performed on subjects during normoglycemia and during acutely induced hyperglycemia. Hyperglycemia was achieved with the ingestion of an oral glucose load. MAIN OUTCOME MEASURES: Changes in retinal arterial and venous blood oxygen saturation resulting from systemic blood glucose changes were measured. Measurements were made using a noninvasive, two-wavelength digital imaging retinal vessel oximeter. RESULTS: In each subject, the measured retinal venous blood oxygen saturation decreased significantly during hyperglycemia. The amount of decrease in venous oxygen saturation associated with hyperglycemia was positively correlated with the duration of diabetes. The measured retinal arterial oxygen saturation did not change significantly during hyperglycemia. CONCLUSIONS: These results, taken with the observations of numerous other investigators that show increased blood flow during acute hyperglycemia, provide evidence of substantially increased retinal oxygen consumption during hyperglycemia. The results also complement previous observations of the effect of diabetes on retinal autoregulation.

Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men.

GH secretion and the response to GH secretagogues are significantly diminished in obese individuals. Previous studies have shown that L-692,429 (L), a nonpeptide mimetic of GH-releasing peptide, selectively stimulates GH release in normal young men and in the elderly, who also have diminished GH secretion. A paired, two-site study examined the effects of L on GH release in 12 healthy obese (part A; mean +/- SD: age, 26.1 +/- 3.3 yr; body mass index, 35.0 +/- 3.1 kg/m2) and 10 nonobese (part B; age, 22.2 +/- 2.3 yr; body mass index, < or = 27.0) young men. In part A, placebo, low dose L (0.2 mg/kg), or high dose L (0.75 mg/kg) was administered iv over 15 min on 3 separate occasions after an overnight fast. Samples for GH, PRL, and cortisol determinations were obtained every 15 min. GH release (mean +/- SE) was significantly increased by both doses of L compared to the effect of placebo: 12.6 +/- 1.8 micrograms/L (low dose), 18.5 +/- 2.7 micrograms/L (high dose), and 0.84 +/- 0.1 microgram/L (placebo), respectively (P < 0.05). In a subset of 6 obese men, in samples collected every 5 min, the GH response to both doses of L was significantly greater than that to 1 microgram/kg GHRH. To compare the response to low dose L in the obese and to determine the effects of feeding on this response, 0.2 mg/kg L was administered as described in part A to nonobese young men after an overnight fast (fasted) or a standardized breakfast (fed; part B). Low dose L was an effective GH secretagogue in nonobese young men; however, this effect was attenuated with feeding [43.6 +/- 7.9 (fasted) vs. 17.7 +/- 4.8 (fed) micrograms/L]. Of note, the response to low dose L in fasted obese individuals was similar to that in fed nonobese individuals. The administration of L was well tolerated in both groups. We conclude that L is an effective GH secretagogue in obese and nonobese young men and may have therapeutic benefits when administered to relative (obese or elderly) or absolute GH-deficient individuals.

Gonadotropin-releasing hormone pulse frequency regulates expression of pituitary follistatin messenger ribonucleic acid: a mechanism for differential gonadotrope function.

Follistatin (FS) is a monomeric glycoprotein that selectively inhibits both secretion of FSH and expression of FSH beta messenger RNA (mRNA), presumably via its ability to bind activin. FS mRNA and protein are present in the gonadotrope, suggesting a local action in regulating FSH beta. Pituitary FS mRNA increases after gonadectomy and at the midcycle gonadotropin surge of the estrous cycle, times of increased GnRH secretion. Thus, the purpose of the present studies was to assess the role of GnRH secretion on the regulation of pituitary FS. To confirm GnRH regulation of FS and to study the role of gonadal steroids, adult male rats were gonadectomized (2-36 h), with some animals receiving either testosterone (T) replacement, LRF-147 (a GnRH antagonist, AC-DTrp1-pCl-DPhe2-DTrp3-Ser4-Tyr5-DArg6-L eu7-Arg8-Pro9-DAla10), or both for 36 h (from the time of castration). Pituitary FS mRNA increased rapidly after castration, with levels rising 3-fold by 12 h and 4-fold by 36 h when compared to intact animals (P < 0.05). This rise was completely abolished by administration of LRF-147 and prevented by T replacement. Because GnRH pulse frequency can selectively regulate FSH beta mRNA expression, we next examined the effect of GnRH pulse interval (8-480 min) on FS mRNA expression. Fast frequency GnRH pulses (8 min), which did not increase FSH beta mRNA, were associated with an increase in FS mRNA (2.5-fold). The 30-min interval increased FS and gonadotropin subunit mRNAs. Slower pulse frequencies (> or = 120 min), which selectively stimulated a rise in FSH beta mRNA, did not increase FS mRNA. These results indicate that pituitary FS mRNA is regulated by GnRH. In addition, GnRH frequency modulation of pituitary FS provides a mechanism whereby a single hypothalamic GnRH can differentially regulate the gonadotropins, LH and FSH.

Ovariectomy and inhibin immunoneutralization acutely increase follicle-stimulating hormone-beta messenger ribonucleic acid concentrations: evidence for a nontranscriptional mechanism.

After ovariectomy (ovx), FSH beta mRNA levels and serum FSH increase 2- to 3-fold within 12 h, and this persists in the presence of a GnRH antagonist. As a fall in plasma estradiol and progesterone appears to regulate FSH beta via increased GnRH secretion, it is thought that the acute (by 2 h) changes in FSH beta mRNA after ovx reflect falling levels of plasma inhibin. The current study addressed the following questions. 1) Does a reduction of circulating inhibin (via passive immunoneutralization or gonadectomy) increase FSH beta mRNA levels? 2) If so, are the acute increases in FSH beta mRNA associated with changes in the transcription rate? Adult male and female rats received 0.5 ml antiinhibin antiserum, iv, and were killed 2 or 12 h later. A second group of rats was gonadectomized; some received a GnRH antagonist and were killed at various intervals between 2 h and 7 days later. In adult males, no change in gonadotropin mRNA levels was observed after either addition of inhibin antiserum or removal of the testes. In contrast, in adult female rats, both ovx and inhibin antiserum increased FSH beta mRNA levels (2-fold) within 2 h, and a similar increase occurred in the presence of a GnRH antagonist. To determine if the increase in FSH beta resulted from increased mRNA synthesis, adult female rats were ovx, and half received a GnRH antagonist. Animals were killed 2 or 12 h later, and transcription rates were measured by nuclear run-off assay in pituitaries pooled from three rats. The transcription rate of the alpha-subunit, although not altered by ovx, was decreased in animals receiving the GnRH antagonist. Transcription of the LH beta gene was increased within 2 h after ovx, a change that was abolished by the GnRH antagonist. mRNA concentrations of either alpha or LH beta do not increase acutely after ovx, suggesting that GnRH regulates alpha and LH beta gene transcription and 12 h or more of mRNA synthesis are required to increase cytoplasmic concentrations. The FSH beta gene transcription rate was unchanged in both ovx and GnRH antagonist-treated animals, but serum FSH increased at 12 h. These data indicate that the rapid GnRH-independent increase in FSH beta mRNA levels seen immediately after ovx is not associated with altered mRNA synthesis and suggest that inhibin may also regulate FSH beta gene expression through nontranscriptional mechanisms.